Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: A cohort study

Annals of Internal Medicine

Volumn 164, Issue 1, 2016, Pages 10-22

  Cleynen, Isabelle ^a   Van Moerkercke, Wouter ^b   Billiet, Thomas ^a   Vandecandelaere, Pieter ^c   Casteele, Niels Vande ^d   Breynaert, Christine ^e   Ballet, Vera ^e   Ferrante, Marc ^e   Noman, Maja ^e   Van Assche, Gert ^e   Rutgeerts, Paul ^e   Van Den Oord, Joost J ^e   Gils, Ann ^d   Segaert, Siegfried ^e   Vermeire, Séverine ^e  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b AZ GROENINGE   (Belgium)

^c AZ Delta   (Belgium)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTINUCLEAR ANTIBODY; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CERTOLIZUMAB PEGOL; CLOBETASOL PROPIONATE; COAL TAR; CORTICOSTEROID; CYCLOSPORIN; DOUBLE STRANDED DNA ANTIBODY; EMOLLIENT AGENT; ETRETIN; INFLIXIMAB; METHOTREXATE; MINOCYCLINE; SALICYLIC ACID; STEROID; TOPICAL ANTIINFECTIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ABSCESS; ACNE VULGARIS; ACUTE FEBRILE NEUTROPHILIC DERMATOSIS; ADD ON THERAPY; ADULT; ALOPECIA; ALOPECIA AREATA; ALOPECIA UNIVERSALIS; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL SUPERINFECTION; BASAL CELL CARCINOMA; CLINICAL FEATURE; COHORT ANALYSIS; CROHN DISEASE; DEMOGRAPHY; DERMATITIS; DERMATOMYCOSIS; DISCOID LUPUS ERYTHEMATOSUS; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; ERYTHEMA NODOSUM; FEMALE; FOLLICULITIS; FOLLOW UP; FUNGAL SUPERINFECTION; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC RISK; GENETIC VARIABILITY; GRANULOMA ANNULARE; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMPETIGO; INFLAMMATORY BOWEL DISEASE; LICHEN PLANUS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MYCOSIS; NAIL DISEASE; NEVUS; PAIN; PANNICULITIS; PERLECHE; PITYRIASIS ROSEA; PRIORITY JOURNAL; PRURITUS; PSORIASIFORM ECZEMA; PSORIASIS; PUSTULOSIS PALMOPLANTARIS; RETROSPECTIVE STUDY; ROSACEA; SEROLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DEFECT; STAPHYLOCOCCUS INFECTION; STEROID THERAPY; STREPTOCOCCUS INFECTION; SUPERINFECTION; SYSTEMIC THERAPY; TERTIARY CARE CENTER; TINEA PEDIS; TOPICAL TREATMENT; ULCERATIVE COLITIS; URTICARIA; VASCULITIS; VERRUCA VULGARIS; VIRAL SUPERINFECTION; VIRUS INFECTION; XEROSIS; XEROSIS CUTIS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DRUG ERUPTIONS; GENETIC PREDISPOSITION; GENETICS; INFLAMMATORY BOWEL DISEASES;

ADULT; DRUG ERUPTIONS; ECZEMA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; PSORIASIS; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84953283895     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-0729     Document Type: Article

References (49)

1. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359:1541-9. [PMID: 12047962].
2. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-33. [PMID: 16472588].
3. Menter A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis. 2009;84:14-24. [PMID: 19916298].
4. Reed MR, Taylor AL. Tumour necrosis factor inhibitors in ankylosing spondylitis. Intern Med J. 2008;38:781-9. [PMID: 18422565].
5. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 2011;60:780-7. [PMID: 21209123].
6. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-76. [PMID: 16339095].
7. Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012;142:257-65.e1-3. [PMID: 22062358].
8. Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Metaanalysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30:339-53. [PMID: 20334454].
9. Bouguen G, Roblin X, Bourreille A, Feier L, Filippi J, Nancey S, et al. Infliximab for refractory ulcerative proctitis. Aliment Pharmacol Ther. 2010;31:1178-85. [PMID: 20222911].
10. Peyrin-Biroulet L. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Minerva Gastroenterol Dietol. 2010;56:233-43. [PMID: 20485259].
11. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-85. [PMID: 16705109].
12. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009; 58:501-8. [PMID: 18832524].
13. Baraliakos X, Listing J, Fritz C, Haibel H, Alten R, Burmester GR, et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years-early clinical response predicts longterm outcome. Rheumatology (Oxford). 2011;50:1690-9. [PMID: 21672969].
14. Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease [Editorial]. World J Gastroenterol. 2009;15:2067-73. [PMID: 19418577].
15. Kircik LH, Del Rosso JQ. Anti-TNF agents for the treatment of psoriasis. J Drugs Dermatol. 2009;8:546-59. [PMID: 19537380].
16. Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA. Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study. Clin Exp Rheumatol. 2012;30:31-8. [PMID: 22153557].
17. Heldmann F, Brandt J, van der Horst-Bruinsma IE, Landewe R, Sieper J, Burmester GR, et al. The European Ankylosing Spondylitis Infliximab Cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol. 2011;29:672-80. [PMID: 21906431].
18. Kievit W, Fransen J, Adang EM, den Broeder AA, Bernelot Moens HJ, Visser H, et al. Long-term effectiveness and safety of TNFblocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register. Rheumatology (Oxford). 2011;50:196-203. [PMID: 21078625].
19. Ngo B, Farrell CP, Barr M, Wolov K, Bailey R, Mullin JM, et al. Tumor necrosis factor blockade for treatment of inflammatory bowel disease: efficacy and safety. Curr Mol Pharmacol. 2010;3:145-52. [PMID: 20799925].
20. Colombel JF, Sandborn WJ, Panaccione R, Robinson AM, Lau W, Li J, et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis. 2009;15:1308-19. [PMID: 19434735].
21. Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9:496-503. [PMID: 22751454].
22. Ettler J, Wetter DA, Pittelkow MR. Pityriasis amiantacea: a distinctive presentation of psoriasis associated with tumour necrosis factor-a inhibitor therapy. Clin Exp Dermatol. 2012;37:639-41. [PMID: 22300412].
23. Afzali A, Wheat CL, Hu JK, Olerud JE, Lee SD. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series. J Crohns Colitis. 2014;8:480-8. [PMID: 24268978].
24. Mateo S, García-Martínez FJ, Sánchez-Aguilar D, Amarelo J, Toribio J. Psoriasiform exfoliative erythroderma induced by golimumab. Clin Exp Dermatol. 2014;39:813-5. [PMID: 25156341].
25. Osório F, Magro F, Lisboa C, Lopes S, Macedo G, Bettencourt H, et al. Anti-TNF-alpha induced psoriasiform eruptions with severe scalp involvement and alopecia: report of five cases and review of the literature. Dermatology. 2012;225:163-7. [PMID: 23052429].
26. Tammaro A, Persechino S, Abruzzese C, Narcisi A, Cortesi G, Parisella FR, et al. Psoriasiform dermatitis in a non-psoriatic patient treated with adalimumab [Letter]. Int J Immunopathol Pharmacol. 2012;25:499-501. [PMID: 22697082].
27. Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014;63:567-77. [PMID: 23468464].
28. Barthel C, Biedermann L, Frei P, Vavricka SR, Kündig T, Fried M, et al. Induction or exacerbation of psoriasis in patients with Crohn's disease under treatment with anti-TNF antibodies. Digestion. 2014; 89:209-15. [PMID: 24853251].
29. Denadai R, Teixeira FV, Steinwurz F, Romiti R, Saad-Hossne R. Induction or exacerbation of psoriatic lesions during anti-TNF-A therapy for inflammatory bowel disease: a systematic literature review based on 222 cases. J Crohns Colitis. 2013;7:517-24. [PMID: 22960136].
30. Rahier JF, Buche S, Peyrin-Biroulet L, Bouhnik Y, Duclos B, Louis E, et al; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048-55. [PMID: 20728573].
31. Ellinghaus D, Baurecht H, Esparza-Gordillo J, Rodríguez E, Matanovic A, Marenholz I, et al. High-density genotyping study identifies four new susceptibility loci for atopic dermatitis. Nat Genet. 2013;45:808-12. [PMID: 23727859].
32. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al; International IBD Genetics Consortium (IIBDGC). Hostmicrobe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-24. [PMID: 23128233].
33. Tsoi LC, Spain SL, Knight J, Ellinghaus E, Stuart PE, Capon F, et al; Collaborative Association Study of Psoriasis (CASP). Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat Genet. 2012;44:1341-8. [PMID: 23143594].
34. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A. 2009;106:9362-7. [PMID: 19474294].
35. Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A, et al. Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet. 2012;90:636-47. [PMID: 22482804].
36. Hanauer SB, Sandborn WJ. European evidence-based consensus on the diagnosis and management of Crohn's disease [Editorial]. Gut. 2007;56:161-3. [PMID: 17303600].
37. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002; 347:417-29. [PMID: 12167685].
38. Vande Casteele N, Ballet V, Van Assche G, Rutgeerts P, Vermeire S, Gils A. Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment [Letter]. Gut. 2012;61:321. [PMID: 21330576].
39. Vande Casteele N, Buurman DJ, Sturkenboom MG, Kleibeuker JH, Vermeire S, Rispens T, et al. Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther. 2012;36:765-71. [PMID: 22928581].
40. Vande Casteele N, Ferrante M, Van Assche G, Ballet V, Compernolle G, Van Steen K, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148:1320-9.e3. [PMID: 25724455].
41. Goyette P, Boucher G, Mallon D, Ellinghaus E, Jostins L, Huang H, et al; International Inflammatory Bowel Disease Genetics Consortium. High-density mapping of the MHC identifies a shared role for HLA-DRB1 01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet. 2015;47:172-9. [PMID: 25559196].
42. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81:559-75. [PMID: 17701901].
43. Baumgart DC, Grittner U, Steingräber A, Azzaro M, Philipp S. Frequency, phenotype, outcome, and therapeutic impact of skin reactions following initiation of adalimumab therapy: experience from a consecutive cohort of inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17:2512-20. [PMID: 21351201].
44. Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al; British Society for Rheumatology Biologics Register Control Centre Consortium. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2009;68:209-15. [PMID: 18385277].
45. Lolli E, Saraceno R, Calabrese E, Ascolani M, Scarozza P, Chiricozzi A, et al. Psoriasis phenotype in inflammatory bowel disease: a case-control prospective study. J Crohns Colitis. 2015;9:699-707. [PMID: 25908719].
46. Wong M, Ziring D, Korin Y, Desai S, Kim S, Lin J, et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol. 2008;126:121-36. [PMID: 17916444].
47. De Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol. 2007;143:223-31. [PMID: 17310002].
48. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-53. [PMID: 16698746].
49. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19 Suppl A:5A-36A. [PMID: 16151544].